Peer Review History
| Original SubmissionSeptember 12, 2022 |
|---|
|
PONE-D-22-25321Monitoring the reproductive number of COVID-19 in France: Comparative estimates from three datasetsPLOS ONE Dear Dr. Bonaldi, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please excuse that this review took so long. I as an editor took over this paper late/recently, and then it was really difficult to find reviewers on my part as well. Please revise the manuscript according to all points of both reviewers. Especially the points of Reviewer 1 should be addressed as well as possible, since his/her recommendation was "reject". Thank you! Please submit your revised manuscript by Aug 25 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Kaspar Staub Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and Additional Editor Comments (if provided): As stated above: Please excuse that this review took so long. I as an editor took over this paper late/recently, and then it was really difficult to find reviewers on my part as well. Please revise the manuscript according to all points of both reviewers. Especially the points of Reviewer 1 should be addressed as well as possible, since his/her recommendation was "reject". Thank you! [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: No Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: I Don't Know Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Thank you for the opportunity to review this manuscript. The authors apply a commonly-used method to three different input sources. The authors seem to be using a “throwing data sets at the wall and see what sticks”-approach. I wonder whether this would be better served as a report from the public health agency rather than a peer-reviewed scientific manuscript; as there does not seem to be much substance for researchers outside of that agency. Additional comments: I would suggest the authors use the short title “Monitoring the reproduction number of COVID-19 in France” rather than “Monitoring the reproduction number” as it makes more sense to split at the colon The authors should provide meta data with their data (following a meta data schema) and should consider depositing their data in a repository such as Zenodo such that it can have a persistent identifier (which can then be used to reference where the data can be accessed). As the authors are using GitHub, there should be an easy plug in allowing for this without too much effort. Line 25: The authors should explain what they mean by “near-real-time” as this is not a common term nor evident from their manuscript. “Real-time” would imply evaluating the next time point (immediately following) but it is unclear what “near-real-time” would be. Line 28: The authors should describe why it “proves challenging”. Presumably due to asymptomatic cases but they could be explicit about it. Line 54: The authors could explain that the effective reproduction number R_t is not the only indicator policy makers might be interested in as it is not informative by itself; additional context is required. For example: an R_t > 1 could be problematic but if additional surge capacity is available in hospitals or most cases not severe does not have to be an issue. Line 57: Is it true that transmission models do not allow for real-time estimation of R_t? It seems to be that there may be contemporary COVID-19-related literature which is relevant here. The references provided by the authors are from the 2000s and more work may have been done in 2020-2022. Line 61-62: “The beginning of the outbreak” is not specific; please provide the date. Line 74: Is the SI-DEP system expected to undergo long-term maintenance or will this data become obsolete in future? Authors need to ensure reproducibility of their work Line 84-86: It is unclear what this means Line 91-92: Were “emergency” units excluded to avoid overlap with the casualty department data? Line 93: Provide estimates of the sensitivity and specificity rates please. If the authors wanted to provide a scientific investigation/modelling study rather than a data analysis they could examine the effects of a higher/lower value of these rates. If doing so a study protocol outlining how the data for examining such a question would be simulated should be deposited to avoid poor scientific practices. The PLOS family of journals supports registered reports, which might be an option to consider. Line 106: Where is the data from these data bases made available (to ensure reproducibility)? Line 112-113: Please provide version numbers and settings used (seeds for pseudo-random number generators etc.) Line 114: A citation is needed for this as well as an explanation of which metrics this statement is made according to Line 116-117: Why not use a weekly aggregated time series in place of this? If “near-real-time” estimation is required, this would presumably be alright (and remove the weekly oscillations in case counts) Line 120: Provide formulae Line 121: Authors should explain why they chose a 95% level Line 130-139: This is not a result but rather a description of the data inputs. Accordingly, it should be moved to the methods section. Line 135-136: This is moreso true for the OSCOUR and SI-VIC data sets which could be mentioned Line 137: The format of the lockdowns should be explained as this is country-specific and the reader may not know what restrictions were in place in France Line 137-139: As this is outside of the study period, it should be removed Line 146-147: See previous comment Line 153-154: But the intervals seem to be non-existent the rest of the time. Is that plausible? Line 162: When this has a temporal dimension, why not show it? Line 169-171: Provide better axis labels Line 172: Which type of correlation is used. Provide the formulae Line 182: But how confident can we be that the signal is correct? Line 182-191: This intuition could be laid out in the beginning Line 197: When is “a few months at the start of the pandemic”? Please provide dates Line 216-218: But how did you quantify this? Line 227-228: Please provide dates for the emergency for France since this is context-specific (depends on local conditions) Line 228-230: Why not do a sensitivity analysis? Change point analysis? Interrupted time series analysis? Line 235: What does “less responsive” mean? Line 242-243: But you noted in line 207-209 that there was a change in the ascertainment (which is super interesting) as your reasoning so that does not seem consistent with this assumption Line 246-247: Would this be included in a Sante Publique France early warning system? Line 261: What about waste water monitoring? Flunet? Other non-invasive options for estimating population-level incidence and prevalence exist Provide an author CReDIT (contributor roles taxonomy) statement Formatting: The authors should ensure consistency of $R_t$ throughout (R$t$ and R) seen as well as the naming (“instantaneous reproduction number” also used in place of “effective reproduction number”). Additionally, the use of R in the introduction is inconsistent with the abstract Line 60: I would suggest the authors use the name Sante Publique France throughout (since it is introduced) Line 77: I would suggest using the term “COVID-19 certificate” rather than “health pass” as the former is more known (being the term used at EU-level) Line 81-82: It should be “EDs” since multiple departments are being referenced Line 84: I would suggest authors used “triage” in place of “coding” to avoid confusion with the concept of coding as it pertains to software code Line 90: I would suggest “health emergency” in place of “unusual health situation” Line 141: This should be “RT-PCR” to be consistent with when the abbreviation was introduced Line 149: R_t falling below 1 is “desired” rather than “expected” Line 156: Should be “Fig 2” Line 272: Should be “Imperial College” In abstract should be date accessed rather than date cited Line 299 and 305: What is “80-“ is there a superfluous hyphen? Check colours are differentiable when printing in black and white In figure 3 could include a dashed line at zero since this is the value of interest for this graph (though perhaps a table would be better) Reviewer #2: This paper applies a method developed by Cori et al (2013) and implemented in the statistical software R to calculate the effective reproduction number Rt during the COVID pandemic in France (May 2020-March 2022) on a daily basis. This method requires some general information on the distribution of the serial interval for the COVID-19, as well as daily incidence data of COVID-19. For the latter, three distinct data sets were used, respectively the daily number of 1) confirmed cases (among those tested), 2) emergency department visits (with suspected COVID), and 3) hospital admissions (due to COVID). Although such data are necessarily incomplete, the Rt obtained were remarkably similar using any of the three data sets, illustrating the fact that a real-time surveillance can be carried out with imperfect data, a useful result for public health. The paper is very well written and clearly publishable. A minor revision would make it even better. I have the following remarks: 1) Statistical method: If feasible, a little more explanation about the method of Cori et al (possibly citing the related paper by Wallinga and Teunis, 2004, American Journal of Epidemiology, 160, 509-516) would be welcome for an interested reader. 2) Discussion: It is written that Rt becomes higher as the mean and standard deviation of the serial interval increase. While this is true for the mean (at least when Rt is greater than 1), Rt would actually decrease with a higher standard deviation, being e.g. overestimated in the extreme case where the standard deviation is wrongly set to 0 (see e.g. Wallinga & Lipsitsch, 2007, Proc. of the Royal Society B, 274, 599-604). This should be corrected. 3) As acknowledged by Cori et al (2013), the serial interval (time between onset of symptoms in the infector and the infected) is used as a proxy of the generation interval (time between infections of the infector and the infected) which should be ideally used in their method. As a direct consequence of my first comment, this should result in an underestimation of Rt since the standard deviation of the generation interval (which should be used) is generally smaller than that of the serial interval (which has been used, see also Ganyani et al, 2020, Euro Surveillance, 25, 2000257). This should be mentioned in the Discussion. 4) In the Discussion, it is briefly mentioned that serial intervals could be shorter with the new Omicron variant. But a shorter serial interval would lead to a smaller Rt, although the Omicron variant was supposed to be much more contagious than the original one, reaching an average Rt of 3.4 (Liu and Rocklov, J. Travel Medicine, 2022, 29, 1-4). How do the authors explain that the peaks in their estimation of the reproduction number did not get that high when new (more contagious) variants appeared? This would deserve one (possibly short) paragraph in the Discussion. 5) Results: “As expected, Rt fell below 1 after the implementation of nationwide lockdown”. It is in fact not obvious to see the effects of the lockdown on such a graphic. These were not the only occasions where Rt fell below 1. Note also that the reproduction number started to rise again before the end of the first lockdown, while it continued to fall well after the second lockdown. One or two sentences recognizing this could be an option (public health is a challenging science!). 6) Caption Figure 2: Write Fig.2 instead of Fig.1. Would you also like to add the relevant dates here (May 2020-March 2022)? ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Monitoring the reproductive number of COVID-19 in France: Comparative estimates from three datasets PONE-D-22-25321R1 Dear Dr. Bonaldi, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Kaspar Staub Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: The authors did a good job in revising this manuscript. I am happy with the revised maanuscript and have no further comments. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: No ********** |
| Formally Accepted |
|
PONE-D-22-25321R1 Monitoring the reproductive number of COVID-19 in France: Comparative estimates from three datasets Dear Dr. Bonaldi: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of PD Dr. Kaspar Staub Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .